SDIX Launches Apo B Antibody in IVD Market

SDIX SDIX today announced its plan to introduce a new polyclonal antisera to its product line for the IVD market. The product, Apo B, will be available as antisera and in fractionated forms. Antibodies to Apo B will be launched on July 26, 2011, at the annual AACC conference in Atlanta, GA. SDIX will be at booth 3755 from July 26-28. SDIX's Apo B can be customized to various automated immunoassay platforms. More specifically, factors such as detection limit, sensitivity, linearity and antigen excess (prozone) can be adjusted and controlled. “Reagent quality and lot-to-lot consistency are both major concerns for immunoassay companies. Selecting an SDIX customized reagent is an easy and efficient solution for these concerns,” commented Paul Dany K, SDIX's IVD Product Manager.